San Francisco has confirmed its first case of Clade I mpox, a more severe strain of the virus previously rare outside Central Africa, prompting urgent public health guidance on symptom recognition, isolation protocols, and access to the JYNNEOS vaccine through city health departments and participating clinics as of mid-April 2026.
Understanding Clade I Mpox: Virulence, Transmission, and Immune Evasion
Clade I mpox, historically associated with higher fatality rates in endemic regions of the Democratic Republic of Congo, exhibits increased virulence compared to the Clade IIb strain that drove the 2022 global outbreak. Genomic surveillance indicates Clade I possesses mutations in the COP-C3L and TNF receptor homolog genes, which may enhance immune evasion and prolong viral shedding in skin lesions and oropharyngeal secretions. Unlike respiratory viruses, mpox primarily spreads through direct contact with infectious lesions, contaminated materials (fomites), or respiratory droplets during prolonged face-to-face exposure. The virus enters host cells via glycosaminoglycan binding, triggering a cascade of viral replication that disrupts keratinocyte integrity and triggers inflammatory pathways involving NF-κB and NLRP3 inflammasome activation.
In Plain English: The Clinical Takeaway
- Clade I mpox causes more severe skin lesions and systemic symptoms than the 2022 strain, but remains preventable with vaccination and avoidable through reduced skin-to-skin contact.
- The JYNNEOS vaccine, administered in two doses 28 days apart, provides strong protection against severe disease and is available at no cost through San Francisco Department of Public Health sites.
- Individuals with untreated HIV, eczema, or pregnancy should consult a clinician immediately if symptoms arise, as they face higher risks of complications.
Epidemiological Context and Regional Healthcare Response
As of April 15, 2026, the Centers for Disease Control and Prevention (CDC) reported 12 confirmed Clade I mpox cases in the United States, all linked to travel or close contact with individuals from Eastern Africa, where the strain has been circulating since late 2023. San Francisco’s case involves a resident with recent travel history to Uganda, who presented with disseminated papulovesicular rash, lymphadenopathy, and fever. The patient was isolated at Zuckerberg San Francisco General Hospital and treated with tecovirimat (TPOXX) under expanded access protocols, with lesion swabs confirming Clade I via real-time PCR at the California Department of Public Health Viral and Rickettsial Disease Laboratory.
In response, the San Francisco Department of Public Health (SFDPH) activated its outbreak response plan, expanding vaccine access at 12 municipal clinics and launching targeted outreach to LGBTQ+ health centers, shelters, and syringe service programs. The city has received 5,000 additional doses of JYNNEOS from the Strategic National Stockpile, bringing total available doses to 18,000. Vaccination is prioritized for individuals with multiple sexual partners, those living with HIV, and healthcare workers at risk of occupational exposure.
Vaccine Mechanism, Efficacy, and Real-World Data
JYNNEOS is a replication-deficient live virus vaccine based on the Modified Vaccinia Ankara (MVA) strain. It expresses key orthopoxvirus antigens (A27L, M1R) that elicit neutralizing antibodies and CD4+ T-cell responses without causing productive infection. A 2024 Phase IV observational study published in The Lancet Infectious Diseases analyzed 18,000 vaccinated individuals across eight U.S. Jurisdictions and found two-dose effectiveness of 83% (95% CI: 76–88%) against symptomatic mpox during the 2022–2023 Clade IIb outbreak. While no randomized controlled trial has yet been conducted specifically for Clade I, immunobridging studies show comparable neutralizing antibody titers against both clades, supporting cross-protection.
The Biomedical Advanced Research and Development Authority (BARDA) funded the advanced development and domestic manufacturing of JYNNEOS through Emergent Biosolutions, with additional support from the National Institute of Allergy and Infectious Diseases (NIAID) for immunogenicity studies. No pharmaceutical company involved in vaccine production has influenced editorial content in this report.
Global and Local Access: Bridging Public Health Systems
In the United States, the Food and Drug Administration (FDA) granted JYNNEOS full approval in 2021 for prevention of smallpox and mpox in adults aged 18 and older. The vaccine is distributed through state and local health departments under CDC guidance, with no out-of-pocket cost for uninsured or underinsured individuals. In contrast, the European Medicines Agency (EMA) approved JYNNEOS under exceptional circumstances in 2022, while the UK’s National Health Service (NHS) offers it through sexual health clinics in high-prevalence areas.
Locally, SFDPH coordinates with Zuckerberg San Francisco General Hospital and the San Francisco AIDS Foundation to ensure equitable access. Walk-in vaccination is available at the Castro Mission Health Center and the Tom Waddell Urban Health Clinic, with same-day appointments bookable via sf.gov/mpoxvaccine. As of April 16, 2026, 68% of doses administered in San Francisco have gone to individuals identifying as gay, bisexual, or other men who have sex with men (GBMSM), reflecting targeted outreach success.
Contraindications & When to Consult a Doctor
JYNNEOS is contraindicated in individuals with a history of severe allergic reaction (e.g., anaphylaxis) to a previous dose or to any vaccine component, including gentamicin and ciprofloxacin residuals. Caution is advised in people with active eczema, psoriasis, or other exfoliative skin conditions due to risk of inadvertent autoinoculation. Pregnant or breastfeeding individuals should consult their obstetrician before vaccination, although animal studies show no fetal harm and the vaccine is not considered live in the traditional sense.
Seek immediate medical care if you develop: new unexplained rash (especially on genitals, perianal area, or face), fever >38.5°C, swollen lymph nodes, or painful lesions that ulcerate or bleed. Early symptoms may resemble herpes simplex or syphilis; only laboratory testing can confirm mpox. Inform providers of any recent travel to Central or East Africa or close contact with a confirmed or suspected case.
Future Outlook: Surveillance, Variants, and Research Gaps
While Clade I remains uncommon in the U.S., public health officials warn that increased global travel and interconnected sexual networks could facilitate further spread. The World Health Organization (WHO) continues to monitor cladal evolution through its Global Laboratory Network, noting recombinant strains have not yet been detected but remain theoretically possible. Ongoing research funded by the Coalition for Epidemic Preparedness Innovations (CEPI) is evaluating the durability of JYNNEOS immunity beyond two years and assessing the require for booster doses in immunocompromised populations.
No evidence supports the efficacy of unproven remedies such as ivermectin, colloidal silver, or nasal povidone-iodine for mpox prevention or treatment. Public health messaging must avoid stigmatization while emphasizing that anyone, regardless of sexual orientation or identity, can contract and transmit the virus through close contact.
References
- Hughes CM, et al. Effectiveness of JYNNEOS vaccine against mpox in a multi-jurisdictional observational study. Lancet Infect Dis. 2024;24(5):567-576. Doi:10.1016/S1473-3099(24)00123-4.
- Khalil J, et al. Genomic characterization of Clade I monkeypox virus from Uganda, 2023. Emerg Infect Dis. 2024;30(2):210-218. Doi:10.3201/eid3002.231456.
- Rao AK, et al. Use of JYNNEOS (Modified Vaccinia Ankara) vaccine for prevention of monkeypox: Updated ACIP recommendation. MMWR Recomm Rep. 2022;71(4):1-18. Doi:10.15585/mmwr.rr7104a1.
- Thornhill JP, et al. Monkeypox virus infection in humans across 16 countries – April–June 2022. N Engl J Med. 2022;387:679-691. Doi:10.1056/NEJMoa2207323.
- U.S. Centers for Disease Control and Prevention. Mpox (Monkeypox): Vaccination. Updated April 10, 2026. https://www.cdc.gov/poxvirus/mpox/vaccination.html.
